| Cash and cash equivalents |
43.62M |
| Trade receivable, net of allowance for doubtful accounts of $90,789 at September 30, 2010 |
| Other receivables |
| Prepaid expenses and other current assets |
| Marketable securities |
| TOTAL CURRENT ASSETS |
49.6M |
| Computers, office equipment and furniture |
| Research equipment |
| Software |
| Leasehold improvements |
| Property, Plant and Equipment, Gross, Total |
| Less: Accumulated depreciation and amortization |
| PROPERTY AND EQUIPMENT, NET |
12.27M |
| Rent deposit |
| Patents |
| Note Receivable, net |
| Derivative asset |
| Investment in Nanotope Inc., equity basis |
| Investment in Leonardo Biosystems Inc., at cost |
| TOTAL OTHER ASSETS |
122.33K |
| TOTAL ASSETS |
85.53M |
| Accounts payable |
5.95M |
| Accrued expenses |
6.26M |
| Accrued payroll and benefits |
1.13M |
| Derivative liabilities |
1.07M |
| Note payable |
144.44K |
| TOTAL CURRENT LIABILITIES |
14.84M |
| Note payable |
2.58M |
| TOTAL LONG-TERM LIABILITIES |
11.27M |
| Commitments and contingencies |
0 |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding |
16 |
| Common stock, $0.001 par value; 145,000,000 shares authorized; 71,833,693 and 71,720,137 shares issued and outstanding as of June 30, 2011 and September 30, 2010, respectively |
152.8K |
| Additional paid-in capital |
| Accumulated deficit during the development stage |
-376.21M |
| Total Arrowhead Research Corporation stockholders' equity |
59.98M |
| Noncontrolling interest |
-555.19K |
| TOTAL STOCKHOLDERS' EQUITY |
59.43M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
85.53M |
